ARID1A and non-Hodgkin lymphoma: We demonstrated that children with MB-NHL harboring ARID1A or TP53 and ARID1A co-mutation were insensitive to initial conventional chemotherapy and subsequent CAR-T treatment and were associated with disease progression or relapse.